Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis

Objectives To evaluate radiographic progression of structural joint damage over 2 years in patients with rheumatoid arthritis from baricitinib clinical trials who were disease-modifying antirheumatic drug (DMARD)–naïve or had an inadequate response to conventional synthetic DMARDs (csDMARD-IR).Metho...

Full description

Bibliographic Details
Main Authors: Désirée van der Heijde, Yoshiya Tanaka, Paul Emery, Li Xie, Michael Schiff, Gabriella Meszaros, Taeko Ishii, Marta Casillas, Robert A Ortmann
Format: Article
Language:English
Published: BMJ Publishing Group 2019-06-01
Series:RMD Open
Online Access:https://rmdopen.bmj.com/content/5/1/e000898.full

Internet

https://rmdopen.bmj.com/content/5/1/e000898.full

Similar Items